+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Oligonucleotide Therapeutics Market 2020-2024 - Product Image

Global Oligonucleotide Therapeutics Market 2020-2024

  • ID: 5017683
  • Report
  • April 2020
  • Region: Global
  • 120 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Biogen Inc.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Miragen Therapeutics Inc.
  • PCI Biotech Holding ASA
  • Sarepta Therapeutics Inc.
  • MORE

Global Oligonucleotide Therapeutics Market 2020-2024

The oligonucleotide therapeutics market, and it is poised to grow by USD 901.18 mn during 2020-2024, progressing at a CAGR of 10% during the forecast period. The reports on oligonucleotide therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of cancer and the need for personalized medicines for neurodegenerative disorders.
The oligonucleotide therapeutics market analysis includes segments as application, technology, and geographic landscape.

The oligonucleotide therapeutics market is segmented as below:

By Application

  • Neurological disorders
  • Cancer
  • Others

By Technology

  • Antisense/RNAi oligonucleotides
  • Others

By Geographic Landscapes

  • North America
  • Europe
  • APAC
  • South America
  • MEA

This study identifies the increased availability of approved drugs as one of the prime reason driving the oligonucleotide therapeutics market growth during the next few years.

The research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of critical parameters. The oligonucleotide therapeutics market covers the following areas:

  • Oligonucleotide therapeutics market sizing
  • Oligonucleotide therapeutics market forecast
  • Oligonucleotide therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position. In line with this, this report provides a detailed analysis of several leading oligonucleotide therapeutics market vendors that include Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Miragen Therapeutics Inc., PCI Biotech Holding ASA, and Sarepta Therapeutics Inc. Also, the oligonucleotide therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of critical parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. This market research report provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biogen Inc.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Miragen Therapeutics Inc.
  • PCI Biotech Holding ASA
  • Sarepta Therapeutics Inc.
  • MORE
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Application
  • Market segments
  • Comparison by Application placement
  • Neurological disorders - Market size and forecast 2019-2024
  • Cancer - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Application
Market Segmentation by Technology
  • Market segments
  • Comparison by Technology placement
  • Antisense/RNAi oligonucleotides - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Technology
Customer landscape
  • Overview
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
Drivers, Challenges, and Trends
  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends
Vendor Landscape
  • Overview
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Alnylam Pharmaceuticals Inc.
  • Arrowhead Pharmaceuticals Inc.
  • Biogen Inc.
  • Dynavax Technologies Corp.
  • GlaxoSmithKline Plc
  • Ionis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Miragen Therapeutics Inc.
  • PCI Biotech Holding ASA
  • Sarepta Therapeutics Inc.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits

1. Key Finding 1
2. Key Finding 2
3. Key Finding 3
4. Key Finding 5
5. Key Finding 6
6. Key Finding 7
7. Key Finding 8
8. Key Finding 9
9. Market in focus
10. Parent market
11. Market characteristics
12. Offerings of vendors included in the market definition
13. Market segments
14. Global - Market size and forecast 2019 - 2024 ($ million)
15. Global market: Year-over-year growth 2019 - 2024 (%)
16. Five forces analysis 2019 & 2024
17. Bargaining power of buyers
18. Bargaining power of suppliers
19. Threat of new entrants
20. Threat of substitutes
21. Threat of rivalry
22. Market condition - Five forces 2019
23. Application placement - Market share 2019-2024 (%)
24. Comparison by Application placement
25. Neurological disorders - Market size and forecast 2019-2024 ($ million)
26. Neurological disorders - Year-over-year growth 2019-2024 (%)
27. Cancer - Market size and forecast 2019-2024 ($ million)
28. Cancer - Year-over-year growth 2019-2024 (%)
29. Others - Market size and forecast 2019-2024 ($ million)
30. Others - Year-over-year growth 2019-2024 (%)
31. Market opportunity by Application
32. Technology placement - Market share 2019-2024 (%)
33. Comparison by Technology placement
34. Antisense/RNAi oligonucleotides - Market size and forecast 2019-2024 ($ million)
35. Antisense/RNAi oligonucleotides - Year-over-year growth 2019-2024 (%)
36. Others - Market size and forecast 2019-2024 ($ million)
37. Others - Year-over-year growth 2019-2024 (%)
38. Market opportunity by Technology
39. Customer landscape
40. Market share by geography 2019-2024 (%)
41. Geographic comparison
42. North America - Market size and forecast 2019-2024 ($ million)
43. North America - Year-over-year growth 2019-2024 (%)
44. Europe - Market size and forecast 2019-2024 ($ million)
45. Europe - Year-over-year growth 2019-2024 (%)
46. APAC - Market size and forecast 2019-2024 ($ million)
47. APAC - Year-over-year growth 2019-2024 (%)
48. South America - Market size and forecast 2019-2024 ($ million)
49. South America - Year-over-year growth 2019-2024 (%)
50. MEA - Market size and forecast 2019-2024 ($ million)
51. MEA - Year-over-year growth 2019-2024 (%)
52. Key leading countries
53. Market opportunity by geography ($ million)
54. Impact of drivers and challenges
55. Vendor landscape
56. Landscape disruption
57. Industry risks
58. Vendors covered
59. Market positioning of vendors
60. Alnylam Pharmaceuticals Inc. - Overview
61. Alnylam Pharmaceuticals Inc. - Business segments
62. Alnylam Pharmaceuticals Inc. - Key offerings
63. Alnylam Pharmaceuticals Inc. - Key customers
64. Alnylam Pharmaceuticals Inc. - Segment focus
65. Arrowhead Pharmaceuticals Inc. - Overview
66. Arrowhead Pharmaceuticals Inc. - Business segments
67. Arrowhead Pharmaceuticals Inc. - Key offerings
68. Arrowhead Pharmaceuticals Inc. - Key customers
69. Arrowhead Pharmaceuticals Inc. - Segment focus
70. Biogen Inc. - Overview
71. Biogen Inc. - Business segments
72. Biogen Inc. - Key offerings
73. Biogen Inc. - Key customers
74. Biogen Inc. - Segment focus
75. Dynavax Technologies Corp. - Overview
76. Dynavax Technologies Corp. - Business segments
77. Dynavax Technologies Corp. - Key offerings
78. Dynavax Technologies Corp. - Key customers
79. Dynavax Technologies Corp. - Segment focus
80. GlaxoSmithKline Plc - Overview
81. GlaxoSmithKline Plc - Business segments
82. GlaxoSmithKline Plc - Key offerings
83. GlaxoSmithKline Plc - Key customers
84. GlaxoSmithKline Plc - Segment focus
85. Ionis Pharmaceuticals Inc. - Overview
86. Ionis Pharmaceuticals Inc. - Business segments
87. Ionis Pharmaceuticals Inc. - Key offerings
88. Ionis Pharmaceuticals Inc. - Key customers
89. Ionis Pharmaceuticals Inc. - Segment focus
90. Merck & Co. Inc. - Overview
91. Merck & Co. Inc. - Business segments
92. Merck & Co. Inc. - Key offerings
93. Merck & Co. Inc. - Key customers
94. Merck & Co. Inc. - Segment focus
95. Miragen Therapeutics Inc. - Overview
96. Miragen Therapeutics Inc. - Business segments
97. Miragen Therapeutics Inc. - Key offerings
98. Miragen Therapeutics Inc. - Key customers
99. Miragen Therapeutics Inc. - Segment focus
100. PCI Biotech Holding ASA - Overview
101. PCI Biotech Holding ASA - Business segments
102. PCI Biotech Holding ASA - Key offerings
103. PCI Biotech Holding ASA - Key customers
104. PCI Biotech Holding ASA - Segment focus
105. PCI Biotech Holding ASA - Segment focus
106. Sarepta Therapeutics Inc. - Overview
107. Sarepta Therapeutics Inc. - Business segments
108. Sarepta Therapeutics Inc. - Key offerings
109. Sarepta Therapeutics Inc. - Key customers
110. Sarepta Therapeutics Inc. - Segment focus
111. Currency conversion rates for US$
112. Research Methodology
113. Validation techniques employed for market sizing
114. Information sources
115. List of abbreviations
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Biogen Inc.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Miragen Therapeutics Inc.
  • PCI Biotech Holding ASA
  • Sarepta Therapeutics Inc.
  • MORE
The research team recognizes the following companies as the key players in the global oligonucleotide therapeutics market: Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Miragen Therapeutics Inc., PCI Biotech Holding ASA, and Sarepta Therapeutics Inc..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increased availability of approved drugs."

According to the report, one of the major drivers for this market is the increasing incidence of cancer.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
4 of 5
  • Alnylam Pharmaceuticals Inc.
  • Arrowhead Pharmaceuticals Inc.
  • Biogen Inc.
  • Dynavax Technologies Corp.
  • GlaxoSmithKline Plc
  • Ionis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Miragen Therapeutics Inc.
  • PCI Biotech Holding ASA
  • Sarepta Therapeutics Inc.
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll